1st Quarter - Report

TIBER CREEK GROUP for ROIVANT SCIENCES, INC.

Firm
Client
Income
$70,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Budget/Appropriations BUD

Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell

LobbyistCovered position, as disclosed
MATTHEW LEFFINGWELL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Pharmacy PHA

Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
ROIVANT SCIENCES HOLDINGS LTD. United Kingdom United Kingdom — —
ROIVANT SCIENCES LTD. Bermuda Bermuda — —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.